Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Department of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Japan.
Osteoporos Int. 2021 Nov;32(11):2323-2333. doi: 10.1007/s00198-021-05995-3. Epub 2021 May 17.
Pre-existing inflammation, corticosteroid therapy, periapical periodontitis, longer duration of denosumab therapy, and female sex were significantly associated with an increased risk of denosumab-related osteonecrosis of the jaw after tooth extraction in patients with cancer on oncologic doses of denosumab. A short drug holiday did not protect against this complication.
This study retrospectively investigated the relationship between various risk factors, including brief discontinuation of denosumab, and development of denosumab-related osteonecrosis of the jaw (DRONJ) after tooth extraction in patients with cancer who were receiving oncologic doses of this agent.
Data were collected on demographic characteristics, duration of denosumab therapy, whether or not denosumab was discontinued before tooth extraction (drug holiday), duration of discontinuation, presence of pre-existing inflammation, and whether or not additional surgical procedures were performed. Risk factors for DRONJ after tooth extraction were evaluated by univariate and multivariate analyses.
A total of 136 dental extractions were performed in 72 patients (31 men, 41 women) with cancer who were receiving oncologic doses of denosumab. Post-extraction DRONJ was diagnosed in 39 teeth (28.7%) in 25 patients. Tooth extraction was significantly associated with development of DRONJ only in patients with pre-existing inflammation (odds ratio [OR] 243.77), those on corticosteroid therapy (OR 73.50), those with periapical periodontitis (OR 14.13), those who had been taking oncologic doses of denosumab for a longer period (OR 4.69), and in women (OR 1.04). There was no significant difference in the occurrence of DRONJ between patients who had a drug holiday before tooth extraction and those who did not.
These findings suggest that inflamed teeth should be extracted immediately in patients with cancer who are receiving oncologic doses of denosumab. Drug holidays have no significant impact on the risk of DRONJ.
在接受地舒单抗肿瘤剂量治疗的癌症患者中,拔牙后发生地舒单抗相关性颌骨坏死(DRONJ)的风险与预先存在的炎症、皮质类固醇治疗、根尖周炎、地舒单抗治疗时间延长以及女性相关。短暂的停药假期并不能预防这种并发症。
本研究回顾性调查了各种风险因素与拔牙后发生地舒单抗相关性颌骨坏死(DRONJ)的关系,这些因素包括短暂停用地舒单抗以及在接受该药物肿瘤剂量治疗的癌症患者中拔牙前是否停用地舒单抗(停药假期)。
收集了人口统计学特征、地舒单抗治疗时间、拔牙前是否停用地舒单抗(药物假期)、停药时间、是否存在预先存在的炎症以及是否进行了其他手术的信息。通过单变量和多变量分析评估了拔牙后发生 DRONJ 的危险因素。
共对 72 例接受地舒单抗肿瘤剂量治疗的癌症患者的 136 颗牙齿进行了拔牙,其中 31 名男性,41 名女性。25 名患者的 39 颗牙(28.7%)诊断为拔牙后 DRONJ。只有在存在预先存在的炎症(优势比 [OR] 243.77)、皮质类固醇治疗(OR 73.50)、根尖周炎(OR 14.13)、接受地舒单抗肿瘤剂量治疗时间较长(OR 4.69)以及女性(OR 1.04)的患者中,拔牙与 DRONJ 的发生显著相关。拔牙前是否有停药假期与 DRONJ 的发生无显著差异。
这些发现表明,对于接受地舒单抗肿瘤剂量治疗的癌症患者,有炎症的牙齿应立即拔除。停药假期对地舒单抗相关性颌骨坏死的风险没有显著影响。